Lenalidomide
- Generic Name
- Lenalidomide
- Indication
⑴主要用于具有5q缺失细胞遗传学异常的骨髓增生异常综合征所致的输血依赖性贫血患者的治疗。⑵与地塞米松合用治疗已经接受过至少一种疗法的多发性骨髓瘤（套细胞淋巴瘤（MCL））患者。
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 250
- Registration Number
- NCT01237249
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸Hospital Ramón y Cajal, Madrid, Spain
🇪🇸Hospital Clínico de Valencia., Valencia, Spain
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 30
- Registration Number
- NCT01199575
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
Revlimid in Transfusion Dependent Patients
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 57
- Registration Number
- NCT01178814
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT00957385
- Locations
- 🇨🇦
University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 24
- Registration Number
- NCT00778752
- Locations
- 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Germany
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Oncology Specialists, S.C.
- Target Recruit Count
- 32
- Registration Number
- NCT00654186
- Locations
- 🇺🇸
Oncology Specialists, S.C, Park Ridge, Illinois, United States
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT00507442
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2006-11-30
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 54
- Registration Number
- NCT00396045
- Locations
- 🇮🇹
Div. Univ. Di Ematologia, Az. Osp. San Giovanni Battista, Torino, Italy
🇮🇹Reparto di Ematologia, Ospedale Ferrarotto, Catania, Italy
🇮🇹Unità Operativa di Ematologia, Spedali Civili, Brescia, Italy
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00360672
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2019-04-12
- Target Recruit Count
- 77
- Registration Number
- NCT00348595
- Locations
- 🇺🇸
The Harry and Jeanette Weinberg Building, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.